Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Crosses Above 200 Day Moving Average – What’s Next?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.42 and traded as high as $4.15. Sonoma Pharmaceuticals shares last traded at $4.04, with a volume of 13,875 shares.

Sonoma Pharmaceuticals Price Performance

The firm’s 50 day moving average is $4.09 and its 200 day moving average is $3.42. The firm has a market cap of $6.63 million, a P/E ratio of -1.64 and a beta of 1.39.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.14. The firm had revenue of $4.01 million for the quarter, compared to the consensus estimate of $4.26 million. Sonoma Pharmaceuticals had a negative net margin of 23.87% and a negative return on equity of 50.00%. As a group, analysts expect that Sonoma Pharmaceuticals, Inc. will post -0.67 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Heron Bay Capital Management bought a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned approximately 2.06% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.